drugset
drugset / Trial / NCT06287567

Lusutrombopag in the Treatment of Immune Thrombocytopenia (ITP)

NCT06287567 ↗

Phase 2 Completed 17 enrolled Institute of Hematology & Blood Diseases Hospital, China
NaSingle-groupOpen-labelTreatment

Summary

This exploratory study is to investigate the efficacy, safety and tolerability of Lusutrombopag in the treatment of primary immune thrombocytopenia in Chinese patients who have failed first-line therapy

Timeline

Start
2024-04-17
Primary completion
2024-11-13
Completion
2025-03-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Lusutrombopag Small molecule 6 mg Oral

Indications

autoimmune thrombocytopenic purpura